Condition: Acute Lymphoblastic Leukemia · Recurrent Acute Lymphoblastic Leukemia · Recurrent B Acute Lymphoblastic Leukemia · Sponsor: St. Jude Children's Research Hospital
This study is a phase I study designed to evaluate the safety of CD19-CD22-CAR T cells. Primary Objective: To determine the safety profile and propose the recommended phase 2 dose (RP2D) of autologous CD19-CD22-CAR T cells in patients ≤ 21 years of age with recurrent/refractory CD19- and/or CD22-positive leukemia. Secondary Objective: To evaluate the anti-leukemic activity of CD19-CD22-CAR T cells.
This description comes directly from the study's public registry record.
Rebecca Epperly, MD · 888-226-4343 · referralinfo@stjude.org
Always discuss trial participation with your own doctor first.
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06777979